Detalhe da pesquisa
1.
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Nature
; 620(7976): 1063-1070, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587335
2.
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Int J Cancer
; 147(8): 2225-2238, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32277480
3.
Patient-Derived Xenograft Models for Ovarian Cancer.
Methods Mol Biol
; 2806: 187-196, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38676803
4.
NETosis as an oncologic therapeutic target: a mini review.
Front Immunol
; 14: 1170603, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37143649
5.
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ther Adv Med Oncol
; 15: 17588359231208674, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38028140
6.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
medRxiv
; 2023 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36993400
7.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Cancer Res
; 82(23): 4457-4473, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206301
8.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Cancer Res
; 81(18): 4709-4722, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34321239
9.
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors.
Cell Death Dis
; 12(3): 268, 2021 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712556
10.
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.
JCO Precis Oncol
; 3: 1-18, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100705
11.
The molecular origin and taxonomy of mucinous ovarian carcinoma.
Nat Commun
; 10(1): 3935, 2019 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31477716
12.
Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab.
Med J Aust
; 199(10): 658, 2013 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24237088
13.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Nat Commun
; 9(1): 3970, 2018 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30266954
14.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 7(9): 984-998, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28588062
15.
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
Crit Rev Oncol Hematol
; 102: 37-46, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27105947
16.
Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1-/- mice.
Cell Death Dis
; 12(12): 1091, 2021 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34789734